Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NOX inhibitor-focused Genkyotex plans IPO

This article was originally published in Scrip

Executive Summary

Genkyotex, a Swiss biotech developing selective NOX inhibitors, has raised CHF20m ($21m) in a series D financing. The money will fund the completion of a Phase II trial of GKT137831 in diabetic nephropathy, advance a second drug into Phase 1 trials, and broaden the company's pipeline of NOX inhibitors. If all goes to plan, the company plans to seek an initial public offering later this year if the markets are still welcoming.

Topics

Related Companies

UsernamePublicRestriction

Register

SC027430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel